One-Year Treatment with Olanzapine Depot in Female Rats: Metabolic Effects

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

One-Year Treatment with Olanzapine Depot in Female Rats : Metabolic Effects. / Ersland, Kari M; Myrmel, Lene S.; Fjære, Even; Berge, Rolf K; Madsen, Lise; Steen, Vidar M; Skrede, Silje.

In: The international journal of neuropsychopharmacology, Vol. 22, No. 5, 2019, p. 358-369.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Ersland, KM, Myrmel, LS, Fjære, E, Berge, RK, Madsen, L, Steen, VM & Skrede, S 2019, 'One-Year Treatment with Olanzapine Depot in Female Rats: Metabolic Effects', The international journal of neuropsychopharmacology, vol. 22, no. 5, pp. 358-369. https://doi.org/10.1093/ijnp/pyz012

APA

Ersland, K. M., Myrmel, L. S., Fjære, E., Berge, R. K., Madsen, L., Steen, V. M., & Skrede, S. (2019). One-Year Treatment with Olanzapine Depot in Female Rats: Metabolic Effects. The international journal of neuropsychopharmacology, 22(5), 358-369. https://doi.org/10.1093/ijnp/pyz012

Vancouver

Ersland KM, Myrmel LS, Fjære E, Berge RK, Madsen L, Steen VM et al. One-Year Treatment with Olanzapine Depot in Female Rats: Metabolic Effects. The international journal of neuropsychopharmacology. 2019;22(5):358-369. https://doi.org/10.1093/ijnp/pyz012

Author

Ersland, Kari M ; Myrmel, Lene S. ; Fjære, Even ; Berge, Rolf K ; Madsen, Lise ; Steen, Vidar M ; Skrede, Silje. / One-Year Treatment with Olanzapine Depot in Female Rats : Metabolic Effects. In: The international journal of neuropsychopharmacology. 2019 ; Vol. 22, No. 5. pp. 358-369.

Bibtex

@article{e8c6cba30a0844008cd03c61382eee1c,
title = "One-Year Treatment with Olanzapine Depot in Female Rats: Metabolic Effects",
abstract = "BACKGROUND: Antipsychotic drugs can negatively affect the metabolic status of patients, with olanzapine as one of the most potent drugs. While patients are often medicated for long time periods, experiments in rats typically run for 1 to 12 weeks, showing olanzapine-related weight gain and increased plasma lipid levels, with transcriptional upregulation of lipogenic genes in liver and adipose tissue. It remains unknown whether metabolic status will deteriorate with time. METHODS: To examine long-term metabolic effects, we administered intramuscular long-acting injections of olanzapine (100 mg/kg BW) or control substance to female rats for up to 13 months. RESULTS: Exposure to olanzapine long-acting injections led to rapid weight gain, which was sustained throughout the experiment. At 1, 6, and 13 months, plasma lipid levels were measured in separate cohorts of rats, displaying no increase. Hepatic transcription of lipid-related genes was transiently upregulated at 1 month. Glucose and insulin tolerance tests indicated insulin resistance in olanzapine-treated rats after 12 months. CONCLUSION: Our data show that the continuous increase in body weight in response to long-term olanzapine exposure was accompanied by surprisingly few concomitant changes in plasma lipids and lipogenic gene expression, suggesting that adaptive mechanisms are involved to reduce long-term metabolic adverse effects of this antipsychotic agent in rats.",
keywords = "diabetes, long-term, olanzapine, rat, weight gain",
author = "Ersland, {Kari M} and Myrmel, {Lene S.} and Even Fj{\ae}re and Berge, {Rolf K} and Lise Madsen and Steen, {Vidar M} and Silje Skrede",
year = "2019",
doi = "10.1093/ijnp/pyz012",
language = "English",
volume = "22",
pages = "358--369",
journal = "International Journal of Neuropsychopharmacology",
issn = "1461-1457",
publisher = "Oxford University Press",
number = "5",

}

RIS

TY - JOUR

T1 - One-Year Treatment with Olanzapine Depot in Female Rats

T2 - Metabolic Effects

AU - Ersland, Kari M

AU - Myrmel, Lene S.

AU - Fjære, Even

AU - Berge, Rolf K

AU - Madsen, Lise

AU - Steen, Vidar M

AU - Skrede, Silje

PY - 2019

Y1 - 2019

N2 - BACKGROUND: Antipsychotic drugs can negatively affect the metabolic status of patients, with olanzapine as one of the most potent drugs. While patients are often medicated for long time periods, experiments in rats typically run for 1 to 12 weeks, showing olanzapine-related weight gain and increased plasma lipid levels, with transcriptional upregulation of lipogenic genes in liver and adipose tissue. It remains unknown whether metabolic status will deteriorate with time. METHODS: To examine long-term metabolic effects, we administered intramuscular long-acting injections of olanzapine (100 mg/kg BW) or control substance to female rats for up to 13 months. RESULTS: Exposure to olanzapine long-acting injections led to rapid weight gain, which was sustained throughout the experiment. At 1, 6, and 13 months, plasma lipid levels were measured in separate cohorts of rats, displaying no increase. Hepatic transcription of lipid-related genes was transiently upregulated at 1 month. Glucose and insulin tolerance tests indicated insulin resistance in olanzapine-treated rats after 12 months. CONCLUSION: Our data show that the continuous increase in body weight in response to long-term olanzapine exposure was accompanied by surprisingly few concomitant changes in plasma lipids and lipogenic gene expression, suggesting that adaptive mechanisms are involved to reduce long-term metabolic adverse effects of this antipsychotic agent in rats.

AB - BACKGROUND: Antipsychotic drugs can negatively affect the metabolic status of patients, with olanzapine as one of the most potent drugs. While patients are often medicated for long time periods, experiments in rats typically run for 1 to 12 weeks, showing olanzapine-related weight gain and increased plasma lipid levels, with transcriptional upregulation of lipogenic genes in liver and adipose tissue. It remains unknown whether metabolic status will deteriorate with time. METHODS: To examine long-term metabolic effects, we administered intramuscular long-acting injections of olanzapine (100 mg/kg BW) or control substance to female rats for up to 13 months. RESULTS: Exposure to olanzapine long-acting injections led to rapid weight gain, which was sustained throughout the experiment. At 1, 6, and 13 months, plasma lipid levels were measured in separate cohorts of rats, displaying no increase. Hepatic transcription of lipid-related genes was transiently upregulated at 1 month. Glucose and insulin tolerance tests indicated insulin resistance in olanzapine-treated rats after 12 months. CONCLUSION: Our data show that the continuous increase in body weight in response to long-term olanzapine exposure was accompanied by surprisingly few concomitant changes in plasma lipids and lipogenic gene expression, suggesting that adaptive mechanisms are involved to reduce long-term metabolic adverse effects of this antipsychotic agent in rats.

KW - diabetes

KW - long-term

KW - olanzapine

KW - rat

KW - weight gain

U2 - 10.1093/ijnp/pyz012

DO - 10.1093/ijnp/pyz012

M3 - Journal article

VL - 22

SP - 358

EP - 369

JO - International Journal of Neuropsychopharmacology

JF - International Journal of Neuropsychopharmacology

SN - 1461-1457

IS - 5

ER -

ID: 226119128